Vietnam Drug Makers Hurt By Ban On Retail Price Increases
This article was originally published in PharmAsia News
Vietnam's drug-making industry is feeling the pain of the government's ban on price increases at the retail level. Drug manufacturers as well as importers, said an industry member at a Drug Administration of Vietnam conference, are being hit by high inflation and an ever-changing exchange rate at the same time. Many drug makers, he said, are forced to use the black market to get the foreign currency they need to buy drugs from abroad. Another noted the price of raw materials needed by local drug makers cost as much as six times more than a year ago. (Click here for more
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.